Cases & Deals

Celgene invests in and enters into strategic collaboration with NantBioScience

Clients Celgene Corporation

Jones Day represented Celgene Corporation, a biopharmaceutical company, in connection with its purchase of $75 million of Series A Preferred Stock in a private placement by NantBioScience, a subsidiary of NantWorks, LLC and a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs. Celgene and NantBioScience concurrently entered into a strategic collaboration to advance research programs to benefit cancer patients in need of new therapeutic solutions.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.